TREE NEWS reports: Chinese innovative drug and CRO concept stocks rallied on Thursday, with Sino Biological touching the 20% daily limit up. Shandong Xinhua Pharmaceutical and Harbin Pharmaceutical Group had each posted two consecutive limit-ups, while Baihua Pharmaceutical, CanSino Biologics and Wanbang Pharmaceutical gained more than 6%.
China Innovative Drug and CRO Stocks Surge; Sino Biological Hits 20% Limit Up
AI take
The breadth of the move — spanning CRO services, innovative biologics and traditional pharma — suggests a sector-wide re-rating rather than a single catalyst. That matters for a market where these names have been sensitive to policy and funding cycles. The open question is whether the rally broadens further or concentrates in a few limit-up leaders.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
18m ago
Boston Dynamics Seeks to Raise at Least $1B Ahead of IPO
1h ago
Robot Concept Stocks Rally in China; Lianhe Precision Seals Limit Up
1h ago
Berkshire Hathaway Boosts Lennar Stake With 2.7M Class A, 75,021 Class B Shares
1h ago
Alibaba to Sell $500M of ZTO Express Shares via Block Trade
1h ago
ChiNext Index Rises More Than 2%
1h ago
China A-share PCB Concept Stocks Extend Rally, Guangzhou Broad Technology and Honghe Technology Hit Limit Up